Incyte Dirección

Dirección controles de criterios 3/4

El CEO de Incyte's es Herve Hoppenot , nombrado en Jan 2014, tiene una permanencia de 10.25 años. compensación anual total es $16.67M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.15% de las acciones de la empresa, por valor de MX$290.90M. La antigüedad media del equipo directivo y de la junta directiva es de 8 años y 7.3 años, respectivamente.

Información clave

Herve Hoppenot

Chief Executive Officer (CEO)

US$16.7m

Compensación total

Porcentaje del salario del CEO	7.4%
Permanencia del CEO	10.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	8.1yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Herve Hoppenot en comparación con los beneficios de Incyte?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

Compensación vs. Mercado: La compensación total de Herve($USD16.67M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD6.04M).

Compensación vs. Ingresos: La compensación de Herve ha sido consistente con los resultados de la empresa en el último año.

CEO

Herve Hoppenot (63 yo)

10.3yrs

Permanencia

US$16,669,368

Compensación

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Herve Hoppenot	CEO & Chairman	10.3yrs	US$16.67m	0.15% $ 291.7m
Christiana Stamoulis	Executive VP & CFO	5.3yrs	US$5.91m	0.011% $ 21.0m
Barry Flannelly	Executive VP & GM of North America	8.9yrs	US$4.62m	0.013% $ 26.5m
Steven Stein	Executive VP & Chief Medical Officer	9.2yrs	US$7.39m	0.0011% $ 2.3m
Pablo Cagnoni	President and Head of Research & Development	less than a year	sin datos	sin datos
Thomas Tray	VP of Finance	2.2yrs	sin datos	0.0035% $ 7.0m
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.3yrs	sin datos	0.016% $ 32.3m
Sheila Denton	Executive VP	less than a year	sin datos	sin datos
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Paula Swain	Executive Vice President of Human Resources	21.8yrs	US$1.31m	0.021% $ 41.4m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0055% $ 10.9m
Jonathan Dickinson	Executive VP & General Manager of Europe	7.9yrs	sin datos	0.010% $ 20.6m

8.1yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de INCY * es experimentado (8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Herve Hoppenot	CEO & Chairman	10.3yrs	US$16.67m	0.15% $ 291.7m
Jean-Jacques Bienaime	Independent Director	9.3yrs	US$484.72k	0.0058% $ 11.6m
Julian Baker	Independent Lead Director	22.5yrs	US$495.47k	0.25% $ 499.5m
Otis Brawley	Independent Director	2.7yrs	US$444.97k	0.0015% $ 3.0m
Jacqualyn Fouse	Independent Director	7.3yrs	US$448.97k	0.0051% $ 10.2m
Edmund Harrigan	Independent Director	4.4yrs	US$451.22k	0.0047% $ 9.5m
Katherine High	Independent Director	4.2yrs	US$454.97k	0.0024% $ 4.9m
Paul Clancy	Independent Director	9.3yrs	US$462.47k	0.0059% $ 11.8m
Susanne Schaffert	Independent Director	1.6yrs	US$294.65k	0.00051% $ 1.0m

7.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de INCY * se considera experimentada (7.3 años de antigüedad promedio).

Incyte Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Chairman recently bought Mex$21m worth of stock

Recent updates

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation Provides Earnings Guidance for 2024

New minor risk - Profit margin trend

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults

Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation

Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

Incyte Corporation Provides Revenue Guidance for the Full Year 2021

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Eli Lilly and Company and Incyte Announce Top-Line Results from BRAVE-AA2

Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as Treatment for Patients with Squamous Cell Anal Carcinoma

Chairman recently bought Mex$21m worth of stock

Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (Ruxolitinib) as A Treatment for Patients with Chronic Graft-Versus-Host Disease

Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Revenue beats expectations

Full year 2020 earnings released: US$1.36 loss per share (vs US$2.08 profit in FY 2019)

Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as A Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (Scac)